Please login to the form below
biosimilars
This page shows the latest biosimilars news and features for those working in and with pharma, biotech and healthcare.
Amgen wins Enbrel patent case, knocking back Sandoz's biosimilar plan
The ruling could delay the arrival of biosimilar competition for Enbrel in the US by a decade. ... If Enbrel remains free from biosimilar competition until 2029, the drug will have enjoyed more than 30 years of intellectual property protection.
Latest news
-
Mega-mergers dominate as buoyant markets lift biopharma
Other highlights from the period include the unexpectedly robust performance of Roche, which has shrugged off the attack of biosimilars in Europe to record a 9% increase in Q2 revenues, and
-
Pfizer set to unveil Mylan merger and spin-off
The latter is a division of Swiss pharma company Novartis, which cut 900 jobs at the generics and biosimilars division in May.
-
New products help lift Roche outlook despite biosimilar onslaught
Two new cancer therapies approved in Q2. Roche has reported a 9% increase in its Q2 revenues, helping it to shrug off an assault on its ageing cancer blockbusters from biosimilars ... This was all achieved despite heavy erosion of sales in Europe thanks
-
Biogen grows in Q2, but Spinraza performance a concern
Company banking on pipeline readouts and Tecfidra defence. Biogen has exceeded expectations in overall Q2 revenues from its multiple sclerosis franchise and biosimilars, but worse than expected performance from its key ... quarter. The company's
-
Von der Leyen elected new European Commission president
On 1 July, a new supplementary protection certificate (SPC) manufacturing waiver was introduced, relaxing the regulations governing the manufacturing of generics and biosimilars in Europe. ... the changes will boost the region’s biosimilar
More from news
Approximately 134 fully matching, plus 306 partially matching documents found.
Latest Intelligence
-
Transitions in healthcare
Switching from an originator biologic to a cheaper biosimilar. These are all examples of the kind of treatment transitions patients experience that can be supported by Patient Support Programmes.
-
It’s not the end of the world, is it?
Whether we market branded products that offer no real superiority over generics, biosimilars or me-toos or we sell innovative products whose price differential is not financially justified, much of what
-
Orphan drugs and breakthrough therapies drive Cortellis Drugs to Watch 2019
It will compete with numerous treatment modalities, including entrenched biological agents and biosimilar biologicals.
-
Drug launches to watch in 2019
The world’s biggest selling drug, Humira, lost its market exclusivity in Europe to biosimilar competition in 2018, and AbbVie is well aware of the impending US patent expiry in 2022. ... Finally, 2019 will see a rapid increase in the uptake of Humira
-
Deal Watch October 2018
None of the other biosimilars in the agreement between the two companies, in the fields of oncology and immunology, are affected. ... Sandoz’s US business has retained its biosimilars, value‐added medicines and complex generics, including the
More from intelligence
Approximately 11 fully matching, plus 56 partially matching documents found.
Latest appointments
-
Ashfield, Health Unlimited and Ashley Communications add to their teams
Van Weperen was most recently at diabetes giant Novo Nordisk, where he worked on delivering insulin and GLP1 biosimilar defence strategies, leading Novo’s UK diabetes team.
-
Lilly bolsters its oncology team
Furthermore, she has been on the forefront of research in oncology vaccines, immuno-oncology and biosimilars, giving her the unique expertise that will be pivotal in helping us continue to develop
-
PharmaLex appoints Zabin Younes as associate director
She joins the group as an associate director and arrives from ERA Consulting - a biopharmaceutical consultancy based in the UK - where she picked up experience in the biosimilar development lifecycle. ... With experience spanning over 15 years, Younes’
-
GW Pharmaceuticals strengthens research and development team
Knappertz has previously held several leadership positions including vice president of clinical development for multiple sclerosis, oncology and biosimilar products at Teva, and numerous clinical and medical roles at Bayer and
-
Sandoz UK promotes Tim de Gavre to country head
Novartis’ generics and biosimilar division Sandoz has appointed Tim de Gavre as its new country head for the UK. ... Our combined portfolio of small molecule generics and biosimilars makes a significant different to medicines costs, and helps the NHS
More from appointments
Approximately 1 fully matching, plus 14 partially matching documents found.
Latest from PMHub
-
Webcast: Navigating new frontiers: Ways to find space in the future RA market
in the European RA market, where their convenient oral administration advantage may override cost considerations that would otherwise favour biosimilar uptake. ... Uptake curve of JAKS compared to other new entrants and biosimilars.
-
Live webinar: Navigating new frontiers: Ways to find space in the future RA market
their convenient oral administration advantage may override cost considerations that would otherwise favour biosimilar uptake. ... Uptake curve of JAKs compared to other new entrants and biosimilars.
-
NHS medicines optimisation milestone
Tackling variations in the uptake of biosimilars locally has been a key focus for RMOCs. ... The best biologics agenda and pharma. In line with the Commissioning Framework for Biological Medicines, NHS England, NHS Improvement and NHS Clinical
-
New local NHS models help to deliver integrated care
A classic example of the way in which this can be achieved can be seen in the development of some biosimilar medicines, which are moving away from infusion to subcutaneous injections
-
The Biosimilar Challenge
These include the infliximab biosimilars Inflectra and Remsima, the etanercept biosimilar Benepali (launched last year) and biosimilars to adalimumab, filgrastim and bevacizumab preparing to launch on the horizon. . ... Biosimilar Cost-Savings in Reality
More from PMHub
Approximately 13 fully matching, plus 23 partially matching documents found.
Featured jobs
- Account Director - Medical Communications - London / South East
-
Excellent Salary and Benefits on offer
- FREELANCE Account Director – Healthcare Advertising – London – 3...
-
Competitive Daily Rates
- Senior Account Executive – Account Manager – Healthcare Advertis...
-
£32000 - £43000 Bonus Benfits
- FREELANCE Medical Writer (Initial 2/ 3 months term) - London Off...
-
Excellent Daily Rate
- Account Director – London based Medical Communications Agency
-
Excellent Remuneration Package
- Account Director, Healthcare Communications
-
Salary TBC
-
Account Director – UK Office
-
Excellent salary and benefits
- Senior Medical Writer, Healthcare Advertising Agency
-
£45, 000 – £50, 000
Subscribe to our email news alerts
- The relevance of patient perspectives to value
- Sanofi patent case win holds off generic rivals for key cancer drug
- Leo Pharma to market AstraZeneca’s brodalumab outside Europe
- Regeneron scores positive data in phase 3 cholesterol trial
- Roche undercuts price of Bayer cancer drug after winning FDA approval
- Putting our core values into practice at the Porterhouse summer social
PMHub
Fishawack Group of Companies
The Fishawack Group of Companies is one of the largest independent medical communications and medical marketing specialists, with teams in...
Latest intelligence
- The relevance of patient perspectives to value
- Exploring the evolution of patient involvement in health technology assessment, and the role of the patient voice in market access....
- How is the NHS Long-term Plan being put into action?
- Steve How, Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore some of the changes that have occurred since the plan was published...
- The evolution of real-world studies
- How industry and regulators are using real-world data...
Quick links
Infographics
